TABLE 1.
Virological and immunological parameters
| Sampling date (mo/day/yr) | Antiretroviral treatmenta | CD4 cell count/mm3 (%)b | No. of HIV-1 RNA copies/ml detected by: |
Major plasma resistance mutation(s)c | Antiretroviral concns (ng/ml) in: |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| AMPLICOR assay |
TaqMan assay |
Abbott real-time assay |
|||||||||
| Plasma | CSF | Plasma | CSF | Plasma | CSF | Plasma | CSF | ||||
| 4/17/02 | None | 311 (6) | 441,660 | ||||||||
| 7/1/02 | d4T, 3TC, NFV | 249 (8) | <200 | ||||||||
| 2/3/03 | <200 | ||||||||||
| 7/7/04 | 87,700 | 54,667 | |||||||||
| 1/26/06 | 356 (6) | 165,000 | RT, no mutation; | ||||||||
| 7/20/06 | ABC, 3TC, ATV/r | 517 (8) | <200 | PRO, L90M | |||||||
| 9/6/06 | 495 (8) | 65,800 | |||||||||
| 11/14/06 | 174 (9) | <20 | <200 | <40 | 440 | ||||||
| 1/12/07 | 504 (14) | <40 | |||||||||
| 3/6/07 | <40 | <400 | 4,229 | 14,610 | ATV, <30; ABC, | ATV, <30; ABC, <10; | |||||
| 4/10/07 | ABC, 3TC, LPV/r | 192 (11) | <40 | 2,060 | 2,047 | 268,980 | 242; 3TC, 625 | 3TC, 144 | |||
| 4/20/07 | LPV, <30; ABC, | LPV, <30; ABC, <10; | |||||||||
| 6/19/07 | <40 | 94; 3TC, <10 | 3TC, 240 | ||||||||
| 8/22/07 | 333 (9) | 59 | |||||||||
| 9/21/07 | 398 (11) | <40 | 1,293 | ||||||||
| 12/11/07 | 248 (12) | 224 | 44,856 | RT, L74V and M184V; | |||||||
| 1/14/08 | AZT, TDF, DRV/r | 2,541 | PRO, I54V and | ||||||||
| 5/9/08 | <40 | <40 | V82F | DRV, 5,784; TDF, 20; FTC, <10 | DRV, <5; TDF, <5; FTC, <10 | ||||||
a
d4T, stavudine; 3TC, lamivudine; NFV, nelfinavir; ABC, abacavir; ATV/r, ritonavir-atazanavir; LPV/r, ritonavir-lopinavir; AZT, zidovudine; TDF, tenofovir; DRV/r, ritonavir-darunavir.
b
Percentage of CD4 cells among total lymphocyte population.
c
Mutations included on the 2008 International AIDS Society list (www.iasusa.org/). RT, reverse transcriptase; PRO, protease.